Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

10 Sökresultat.
Relevans Bedömning Nya först Gamla först

Cutaneous End Organ Assessments Week 38 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 38

- 2017-07-15 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 32 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 32

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 32.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 28 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 28

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 28.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 24 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 24

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 24.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 20 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 20

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 20.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 16 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 16

- 2017-07-12 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 12 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 12

- 2017-07-10 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 12.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 8 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 8

- 2017-07-09 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 8.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Week 4 Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Week 4

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Week 4.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Cutaneous End Organ Assessments Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Cutaneous End Organ Assessments Day 1 Pre-Infusion

- 2017-06-11 - 1 Formulär, 1 Item-grupp, 5 Dataelement, 1 Språk
Item-grupp: Assessments Cutaneous
Study part: Cutaneous End Organ Assessments Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial